Clinical Trial

Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)

Name: Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) — clinical trial record (NCT07283692)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.

Protocol Amendment History 1 change

critical Recruitment opened 2026-05-14

Trial Details

NCT Number	NCT07283692
Lead Sponsor	RenJi Hospital
Conditions	Triple Negative Breast Cancer
Enrollment	46 participants
Start Date	2026-03-01
Primary Completion	2026-12 (estimated)
Study Completion	2031-09 (estimated)
Updated on ClinicalTrials.gov	2026-05-13